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Abstract: Juvenile idiopathic arthritis (JIA) is a group of chronic arthritides affecting children. 
The polyarthritis category, affecting five or more joints in the first six months, tends to be 
more aggressive, leading to a destructive joint disease with significant morbidity, disability, 
and costs to society. The current treatment regimen, which primarily combines methotrexate 
and tumor necrosis factor alpha (TNF-α) blockade, still leaves a significant group of patients 
with an inadequate response. Therefore, the development of new medications that act via other 
mechanisms of pathogenesis is necessary. T cell lymphocytes are key components in the immune 
reaction in JIA. Cytotoxic lymphocyte-associated antigen-4 (CTLA-4) is a potent inhibitor of 
the costimulation pathway necessary to activate T cells. Abatacept is a recombinant fusion 
protein comprising the extracellular part of human CTLA-4 connected to a modified Fc part of 
IgG-1. In a randomized, multinational, blinded withdrawal study in children with polyarticular 
JIA, abatacept was found to be effective in about 70% of the patients, including 39% of TNF-α 
blockade failures, with significantly fewer flares occurring during the withdrawal phase than in 
patients receiving placebo. Abatacept continued to show good efficacy in a three-year open-label 
extension study, with a beneficial effect on health-related quality of life. The safety profile of 
abatacept is generally good. In 2008, the US Food and Drug Administration approved abatacept 
for use in children over six years of age with JIA and a polyarticular course. In 2010, the European 
Medicines Agency gave approval for abatacept to be used in combination with methotrexate for 
those who fail at least one disease-modifying medication and TNF-α blockade.
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Introduction
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic condition in 
children, affecting approximately 1 in 1000 children.1 It is an inclusive term for a group 
of chronic inflammatory arthritides affecting children younger than 16 years of age, 
without another explanation.1,2 The categories are based on the presence or absence of 
systemic symptoms or psoriasis, the number of joints involved in the first six months of 
the disease, rheumatoid factor, and HLA B27 status (Table 1). The polyarthritis category 
includes children with five or more affected joints during the first six months of the 
disease, and is further subdivided according to rheumatoid factor status. This form of 
JIA tends to be more aggressive (especially rheumatoid factor-positive disease), caus-
ing joint destruction and disability early in its course, with radiographic changes 
evident at a mean of two years from disease onset.2 The inflammatory process can be 
difficult to control, and consequences include pain, disability,3 local and global growth 
impairment,4 and major insults to function and health-related quality of life for the Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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patient and his/her family.5 A significant percentage of patients 
with   polyarthritis continue to have active disease as adults.3,6 
The disease affects multiple aspects of life, and carries a 
heavy economic burden for society. Understanding this has 
led to an earlier and more aggressive treatment regimen, 
with early introduction of disease-modifying antirheumatic 
drugs, particularly methotrexate.7,8 However, more than 
30% of patients do not respond adequately to methotrexate, 
including higher doses given parenterally.8,9 Full remission 
is usually not achieved, even among responders. Therefore, 
new biologic medications based on an understanding of the 
immune pathogenesis of JIA have been developed. This has 
revolutionized the treatment of JIA, particularly in patients 
with a polyarticular course (Table 1). Polyarticular course 
includes patients with polyarthritis, extended oligoarthritis, 
and systemic arthritis evolving into a polyarticular course. 
Most studied are the tumor necrosis factor alpha (TNF-α) 
blockers.10–12 More than 70% of patients with JIA having a 
polyarticular course and treated with TNF-α blocking agents 
respond significantly. However, a large proportion of children 
with polyarthritis still spend more than 60% of their time with 
active disease.13 For patients who do not respond adequately 
to TNF-α blocking agents, for whom effectiveness wears 
off, or for those who cannot tolerate or use TNF-α blockers, 
there is still an unmet need.14,15 Therefore, new medications 
that target different mechanisms of pathogenesis have been 
developed. In this paper, we review the rationale and current 
data for the use of abatacept, a selective T cell costimulation 
inhibitor, in JIA with a polyarticular course.
Role of T cells in pathogenesis  
of JIA
Data on the pathogenesis of JIA are continuously 
accumulating, with research focusing on genetic factors 
and various pathways of the immune system. T cells have a 
crucial role in initiating the cascade of the immune response 
in JIA. Increased numbers of activated CD4+ and autoreactive 
CD8+ T cells are found in the circulation and the synovium 
of patients with JIA of polyarticular course.16 No specific 
antigens that trigger T cell activation have been recognized, 
but there are two major hypotheses on potential autoantigen 
groups. These include heat shock proteins and epitopes 
from the components of joint tissue found in the inflamed 
synovium. The synovial fluid from patients with JIA of 
polyarticular course was found to contain higher levels of 
cytokines (including interleukin [IL]-12) and chemokines 
that upregulate the immune response.16 Activated oligoclonal 
T cells that originate in the blood are concentrated in the 
synovial fluid in larger numbers in JIA.17 IL-17, produced 
by subsets of CD4+ cells in the synovium, was recognized to 
induce further local production of cytokines by synoviocytes, 
especially IL-6, IL-8, and matrix metalloproteinases that 
enhance joint destruction. IL-17 also suppresses Tregs 
(CD4+CD25+) activity. Tregs have an important role in 
the process of autoimmune disease prevention, and have 
been found in decreased numbers in patients with JIA of 
polyarticular course compared with those having persistent 
oligoarthritis.18
Abatacept
The activation of T cells involves two major steps. The first 
consists of the presentation of a peptide by an antigen-presenting 
cell to the T cell receptor (Figure 1).19 The second step can 
be one of several costimulation associations between ligands 
on the antigen-presenting cell and T cell receptors. One 
of the most important is the link between the CD80/CD86 
ligand on antigen-presenting cells and CD28 on T cells. 
CTLA-4 (CD152) is a member of the CD28 immunoglobulin 
superfamily expressed on the T cell membrane. It has a 
structural resemblance to CD28, but its affinity to CD80/CD86 
is much higher. CD28 transmits a stimulatory effect, enhancing 
activation and upregulation of downstream pathways. CTLA-4 
transmits an inhibitory signal to T cells and thus decreases 
activation of B cells, macrophages, and production of 
proinflammatory cytokines, and induces anergy.20 Abatacept 
(CTLA-4 immunoglobulin) is a recombinant fully humanized 
fusion protein, composed of the extracellular domain of human 
CTLA-4 and a portion of the Fc-domain of human IgG-1 that 
was engineered to prevent complement fixation.21
Trials in adults with rheumatoid arthritis demonstrated 
improvement in disease control, health-related quality of 
life, and reduction in joint damage in patients who failed to 
Table 1 Categories of juvenile idiopathic arthritis
Category Proportion of patients (%)
*Systemic 5–10
Oligoarthritis 40–50
  Persistent oligoarthritis 25–35
  *extended oligoarthritis 15–20
Polyarthritis 30–40
  *Rheumatoid factor-negative 25–35
  *Rheumatoid factor-positive 5
Psoriatic arthritis 5–10
enthesitis-related arthritis 5–10
Other (undifferentiated, overlaps  
more than one category)
10
Note: *Patients in these categories with polyarticular disease (and without active 
systemic features) were included in the abatacept trials.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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respond to other disease-modifying antirheumatic drugs.22 
Abatacept was approved for rheumatoid arthritis by the US 
Food and Drug Administration (FDA) in 2005.
Pharmacokinetics  
and pharmacodynamics
The pharmacokinetics of abatacept have not been   specifically 
examined in children or adolescents, and are based on   studies 
in healthy adults and patients with rheumatoid   arthritis.23 
  Pharmacokinetics in healthy adults were examined after a   single 
dose of abatacept and in rheumatoid arthritis patients after mul-
tiple doses of 10 mg/kg (both groups were comparable).24 The 
mean volume of distribution was 0.07 (range 0.02–013) L/kg. At 
steady state, the plasma concentration level achieved at day 60 
was 24–295 µg/mL. The half-life was 13.1 (range 8–25) days. 
The systemic clearance was 0.22 mL/kg/hour, with a trend 
of increased clearance with increased body weight. Systemic 
accumulation was not demonstrated after prolonged therapy. 
Concomitant treatment with methotrexate, nonsteroidal anti-
inflammatory drugs, corticosteroids, or TNF-α blockers did not 
change the clearance. Pharmacokinetics were not affected by 
age and gender. The influence of renal or hepatic   dysfunction 
on pharmacokinetics was not studied.
Abatacept pharmacodynamics at a dose of 10 mg/kg 
showed a decrease in serum levels of several cytokines and 
acute-phase reactants, particularly C-reactive protein, TNF-α, 
IL-6, and metalloproteinase-3.
Efficacy of abatacept in JIA  
of polyarticular course
Abatacept was studied in a randomized, double-blind, 
  placebo-controlled withdrawal trial performed in 45 
  centers in Europe and the US between 2004 and 2006.25 
The study was conducted in European and South American 
centers of the Pediatric Rheumatology International Trials 
Organization and in the US by the Pediatric Rheumatology 
Collaborative Study Group. Children aged 6–17 years 
with a polyarticular course of JIA were enrolled, including 
patients with polyarthritis with and without rheumatoid 
factor, extended oligoarthritis, and systemic JIA without 
systemic manifestations for at least six months. At the time 
of enrollment, patients had to have at least two active joints 
and two joints with limited range of motion. Patients had to 
have failed or not tolerated at least one disease-modifying 
antirheumatic drug. Patients failing TNF-α blocking agents 
were allowed to enroll after an adequate washout period 
(four weeks for etanercept and eight weeks for infliximab 
and adalimumab). Exclusion   criteria included active 
uveitis, pregnancy, lactation, or a major concurrent medical 
condition. Methotrexate was the only disease-modifying 
antirheumatic drug allowed during the controlled phase of 
the trial (hydroxychloroquine, sulfasalazine, and azathioprine 
were allowed during the open-label, long-term extension). 
Patients were primarily assessed using the American   College 
of Rheumatology (ACR) Pediatric 30, an outcome tool 
developed in the 1990s that has been validated as an outcome 
measure in JIA trials (Table 2).26 The proportions of patients 
with an ACR   Pediatric 50, 70, 90, and 100 response were 
also assessed.
One hundred and ninety patients entered the open-label, 
lead-in phase of the study; 147 (77%) were Caucasian, and 137 
(72%) were females (Figure 2). Rheumatoid factor-  negative 
polyarthritis was the most common diagnosis (44%). The 
mean disease duration was 4.2 years. Patients had a mean of 
16 active joints. More than 70% were treated with concurrent 
methotrexate, and more than 30% had been treated unsuc-
cessfully with at least one TNF-α blocking agent. In the first 
phase, all patients received abatacept 10 mg/kg   (maximum 
1000 mg per dose) on days 1, 15, 29, 57, and 85. Seventeen 
patients discontinued because the treatment was ineffective, 
one withdrew because of an adverse effect, one was lost to 
follow-up, and no reason was stated for one patient. By the 
end of the lead-in phase, 123 subjects (65%) were considered 
MHC
TCR
CD28
CD80/CD86
Abatacept
Inactive
T cell
APC
Figure 1 Schema of T cell activation and the inhibitory action of abatacept on 
costimulation. Copyright © 2008. Dove Medical Press. Reprinted with permission. 
Kuemmerle-Deschner JB, Benseler S. Abatacept in difficult-to-treat JIA. Biologics. 
2008;2(4):865–874.31
Abbreviations: APC, antigen presenting cell; MHC, major histocompatibility complex; 
TCR, T cell receptor.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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responders at least at an ACR Pediatric 30 response level. 
Twenty-four (13%) patients attained a status of inactive 
disease (definition in Table 3). There were no significant 
differences in response rates between the various categories 
of JIA with a polyarticular course.
The pivotal phase was double-blind withdrawal 
  randomization to abatacept versus placebo. One hundred 
and twenty-two subjects (one eligible subject left the study 
before randomization) entered this phase on day 113, with 
60 randomized to abatacept and 62 to placebo infusion 
 ( Figure 2). Treatment was administered every 28 days until 
the development of an arthritis flare (definition in Table 2A) 
for up to six months. The primary outcome was the   number 
of patients in each arm of the study who flared within 
these six months. Secondary outcomes included safety and 
tolerability of the drug, median time to disease flare, and other 
ACR Pediatric response rates at the end of six months. The 
number of patients who developed a flare was significantly 
lower in the abatacept group compared with the placebo 
group (12 [20%] versus 33 [53%], respectively, P = 0.0003). 
The median time to flare in the placebo group was six months, 
but no calculation was possible in the abatacept groups due 
to insufficient events. Significantly more patients in the 
abatacept group achieved an ACR Pediatric 50, 70, and 90 
response rate, as well as inactive disease status, than in the 
placebo group (Table 4). A full six months was completed 
by 49 (82%) patients in the abatacept group and 31 (50%) 
in the placebo group.
Following this phase was an open-label, long-term, 
extension period in which patients were given the option 
to continue treatment with abatacept for up to five years.27 
Subjects included in this phase belonged to several groups, 
ie, patients treated continuously with abatacept, those with 
a flare during the double-blind phase, and six-month com-
pleters regardless of the treatment arm. Patients who did not 
achieve an ACR Pediatric 30 after the open-label phase were 
also allowed to enter the long-term extension. Patients were 
assessed by joint examination and physician’s global assess-
ment of disease severity.
Forty-two of 153 subjects who started this phase discon-
tinued treatment early; 20 due to lack of effect (more than 
half were from the group of the initial nonresponders) and 
three because of adverse effects. Patients were treated for a 
median of 35 (range 5.5–47.8) months. More than 50% were 
treated for at least three years. Fifty-one patients were treated 
continuously with abatacept, and treatment was interrupted in 
47 patients due to having received placebo during the double-
blind phase. ACR Pediatric response rates at day 589 did 
not significantly differ between these two groups (Table 3). 
However, significantly more patients in the continuous group 
(22 patients, 43%) attained the status of inactive disease than 
in the interrupted group (11 patients, 22%).
Sixteen of the 36 patients who did not achieve an ACR 
Pediatric 30 by the end of the open-label lead-in phase who 
entered the long-term extension phase stopped treatment early; 
11 because of loss of efficacy, one because of loss to follow-up, 
and four without a documented reason. The response rate of this 
group was lower than those who responded in the open-label, 
lead-in phase, with only one subject attaining the status of 
inactive disease (Table 4). However, it is important to note that 
there was still a large number of responders (including at high 
levels of an ACR Pediatric 50 and 70 response) indicating that 
a long trial of abatacept (even six months) may be necessary 
before a patient is considered to have failed treatment.
Patients naïve to TNF-α blockade 
versus TNF-α blockade failures
AWAKEN (Abatacept Withdrawal study to Assess efficacy 
and safety in Key ENdpoints) was the first trial to include 
JIA patients who had failed TNF-α blockade. One hundred 
and thirty (70%) of the subjects in the AWAKEN trial were 
naïve to TNF-α blockade. By the end of the open-label, 
lead-in phase, 101 (76%) achieved an ACR Pediatric 30 
response, compared with 57 (39%) patients who failed 
Table 2 Outcome measures for clinical trials in juvenile idiopathic 
arthritis validated by the American College of Rheumatology26
•   Active joint count (joints with swelling or tender/pain on motion and 
limitation of motion)
• Joints with limited range of motion
• Parent/patient global assessment (measured on a 0–10 vAS)
• Physician global assessment (measured on a 0–10 vAS)
•   Laboratory measure of inflammation (erythrocyte sedimentation rate, 
C-reactive protein)
• Functional assessment (Childhood Health Assessment Questionnaire)
Notes: ACR Pediatric 30 response: A patient is considered to have responded if 
there has been an improvement in at least three variables by at least 30% and 
worsening in not more than one variable by more than 30%. Flare: A patient is 
considered to flare if there has been worsening of 30% or more in at least three 
of the six variables and at least 30% improvement in no more than one variable. 
A minimum change of 20 mm in global assessment and at least two additional active 
joints is necessary.
Abbreviation: vAS, visual analog scale.
Table 3 Definition of inactive disease.6
• No joints with active disease
• Normal erythrocyte sedimentation rate (,20 mm/hour)
• Physician global assessment of 10 mm or less
• No uveitisDrug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Completed lead-in phase
n = 170
Open label lead-in phase
n = 190 
Discontinued
n = 20  
Achieved ACR Pedi 30
n = 123
Failed ACR Pedi 30
n = 47 
Abatacept
n = 60
Placebo
n = 62
Completed
n = 49 
Completed
n = 31
Remaining
n = 48*
Remaining
n = 43*
Remaining
n = 20*
6 months 
4 months 
Discontinued
n = 11 
Discontinued
n = 31
LTE
n = 58
LTE
n = 59
LTE
n = 36
Figure 2 A flow chart of patient disposition in various phases of the abatacept trial.27
Note: One responder was not randomized. 
Abbreviations: ACR, American College of Rheumatology; Pedi, pediatric; LTe, long-term extension.
TNF-α blocking agents in the past. The response rate of 
continuous abatacept treatment on day 589 was similar 
among the TNF-α blockade-naïve subjects (n = 46) and 
TNF-α blocking agent failures (n = 5). However, inactive 
disease status was attained in 46% of the TNF-α blockade-
naïve group, versus 20% in the latter group (Table 5). The 
response rate for interrupted abatacept (placebo during the 
double-blind phase and reintroduction of abatacept during 
the long-term extension) treatment was greater among the 
TNF-α blockade-naïve group than the TNF-α blocking 
agent failures, especially among those who attained a high 
response rate and/or inactive disease status (Table 5). No Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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significant differences in response rates between TNF-α 
blockade-naïve and failures were found in nonresponders in 
the open-label, lead-in phase who continued to the long-term 
extension. Among the five TNF-α blocking agent failures, 
80%, 60%, and 20% achieved an ACR Pediatric 30, 50, and 
70 response rate, respectively.
Health-related quality of life,  
pain, sleep, and daily activities
Abatacept improves many aspects of the children’s health-
related quality of life.28 Health-related quality of life were 
assessed using the Child Health Questionnaire (CHQ), a 
validated tool translated into 32 languages. Two summary 
scores, ie, the physical summary score and the psychosocial 
summary score, were calculated from analysis of 10 of 15 CHQ 
domains. Results were compared with healthy individuals.29 
Pain was assessed by parents or caregivers using a 100 mm 
visual analog scale in which a higher score is worse. Sleep 
was assessed using the Children’s Sleep Habits Questionnaire 
which includes the following subcategories: bedtime resis-
tance, sleep onset delay, sleep duration, sleep anxiety, night 
waking, parasomnias, sleep-disordered breathing, and day-
time sleepiness. Total scores of 1–100 correlate directly with 
the magnitude of sleep disturbances. Participation in daily 
activities was assessed with a questionnaire that addressed 
school attendance and the effect of JIA on the child and care-
givers’ daily activities over the 30 days prior to answering. 
All assessments were performed three times in the open-label 
lead-in and the controlled withdrawal phases of the trial.
Health-related quality of life parameters were significantly 
decreased in the study subjects when compared with healthy 
children at baseline, such as global health, physical function, 
role/social limitations (emotional, role/social limitation), 
physical and pain/discomfort. These improved significantly 
by the end of the open label, lead-in phase, with the physical 
summary score increasing in ACR Pediatric 30 responders 
to 42.5 (maximum = 55) at day 113. During the controlled 
withdrawal phase, health-related quality of life continued 
to improve in subjects who were randomized to continue 
abatacept, but stabilized or worsened in the placebo group. 
Pain was reduced in all subjects during the open-label, 
lead-in phase and in abatacept-treated patients during the 
controlled withdrawal phase. However, pain increased in the 
placebo-treated group. Reduction of pain was observed also 
in patients who did not achieve an ACR Pediatric 30 response 
after the lead-in phase.
Following the open-label, lead-in phase, sleep index 
scores improved among ACR Pediatric 30 responders, 
mainly in the domains of bedtime resistance, parasomnias, 
and daytime sleepiness. Sleep continued to improve in the 
abatacept-treated subjects during the controlled withdrawal 
phase, but deteriorated in the placebo-treated subjects.
Following the open-label, lead-in phase, the ACR Pediatric 
30 responders missed fewer school days (2.6) per month and 
Table 4 Response (percent) to therapy during various phases of the trial
Percent of patients achieving Level Pedi 30 Pedi 50 Pedi 70 Pedi 90 Pedi 100 Inactive disease
Lead-in open-label (n = 190) 65 50 28 13 NA 13
DB abatacept (n = 60) 82 77* 53* 40* NA 30*
DB placebo (n = 62) 69 52* 31* 16* NA 11*
LTe continuous abatacept (n = 51), day 589 90 88 75 57 20 43*
LTe interrupted treatmenta (n = 47), day 589 87 83 75 40 19 22*
LTe lead-in phase nonresponders (n = 22), day 589 73 64 46* 18* 0* 3*
Notes: aPatients who received placebo during the double-blind withdrawal phase; *Statistically significant differences.
Abbreviations: Pedi, American College of Rheumatology pediatric response rate; DB, double blind; LTe, Open-label long-term extension; NA, not available.
Table 5 Comparison of the response rate (percent) of patients who were TNF-α blockade-naïve versus TNF-α blockade failures at 
day 589 of the open-label long-term extension period
Patients achieving level (%) Pedi 30 Pedi 50 Pedi 70 Pedi 90 Pedi 100 Inactive disease
Continuous abatacept, TNF-α blockade-naïve (n = 46) 89 87 76 57 39 46
Continuous abatacept, TNF-α blockade failure (n = 5) 100 100 60 60 40 20
interrupted abatacept, TNF-α blockade-naïve (n = 41) 90 88 81* 46* 22* 24*
interrupted abatacept, TNF-α blockade failure (n = 6) 67 50 33* 0* 0* 1*
Nonresponders in lead-in phase, TNF-α blockade-naïve (n = 17) 71 65 53* 24* 6 6
Nonresponders in lead-in phase, TNF-α blockade failure (n = 5) 80 60 20* 0* 0 0
Note: *Statistically significant difference.
Abbreviations: Pedi, American College of Rheumatology pediatric response rate; TNF-α, tumor necrosis factor alpha.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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their parents missed fewer days (2.3) of their normal   activities. 
These effects continued only among abatacept-treated subjects 
during the controlled withdrawal phase.
Safety
The safety profile of abatacept was generally good and 
essentially remained unchanged during all phases of the 
study (Table 6). In the open-label, lead-in phase, six subjects 
had serious adverse events that included arthritis flare in two 
patients and arthropathy in another. There was one case each 
of varicella infection, ovarian cyst, and acute lymphoblastic 
leukemia diagnosed at day 89. The latter patient may have been 
misdiagnosed with JIA. Adverse events were documented in 
133 (70%) subjects. The most common adverse events were 
headache (13%), nausea (10%), cough, diarrhea (9% each), 
upper respiratory tract infection (7%), and pyrexia (6%). Mild 
infusion reactions were documented in eight patients (4%). 
These included headache and dizziness and did not recur.
In the controlled withdrawal phase, no serious adverse 
events were documented in the abatacept group. There were 
two serious adverse events in the placebo group that included 
hematoma and varicella with encephalitis. Both resolved 
  without sequelae. In regards to serious adverse events in 
the placebo group, it is important to note that these patients 
received four months of abatacept, and a long-term effect of 
abatacept on the immune system cannot be ruled out. Adverse 
events were reported in 37 (62%) from the abatacept group 
and 34 (55%) among placebo recipients (P = 0.47), with mild 
infections being the most frequent. Mild infusion reactions 
occurred in 2%–3% of patients in both study arms. No other 
serious infections, autoimmune disorders, or anaphylaxis 
developed.
In the long-term extension, 23 subjects developed serious 
adverse events (Table 6). These included arthritis flare (n = 6), 
arthralgia, foot deformity, pyrexia, and vomiting (n = 2 
each). The most common adverse events were infections, 
with nasopharyngitis developing in 17.6%, upper respiratory 
tract infections in 16.3%, vomiting in 15%, and pyrexia in 
14%. Serious infections developed in six subjects, includ-
ing dengue fever, erysipelas, gastroenteritis, herpes zoster, 
bacterial meningitis, and pyelonephritis. One case of uveitis 
and four cases of benign neoplasm developed. One patient 
developed multiple sclerosis. No cases of mycobacterium, 
opportunistic infections, or malignancies were observed. 
Mild infusion reactions were uncommon. There were no 
significant laboratory abnormalities. Following the open-
label, lead-in phase, antinuclear antibodies developed in 
12 of 113 (10.6%) subjects who were initially antinuclear 
antibody-negative. In the double-blind phase, new antinuclear 
antibodies developed in two (6%) of the abatacept group 
and one (2%) in the placebo group. The development of 
double-stranded DNA antibodies was rare. None of those who 
developed autoantibodies developed autoimmune disease. 
Antibodies to abatacept or to CTLA-4 developed in 23% of 
the patients. Their presence did not influence the efficacy or 
safety of abatacept.
A 2009 FDA pediatric advisory committee meeting 
looked at five-year postmarketing data of 90 patients treated 
with abatacept for up to 10 years until the age of 17 years.30 
Six serious adverse events (four in the US) were reported. 
Four patients were treated for JIA and three for other indica-
tions. Serious adverse events included the aforementioned 
case of multiple sclerosis and lymphoma that occurred one 
month after starting abatacept. This patient had vasculitis 
and was treated with many prior immunosuppressive medi-
cations. The FDA has requested postmarketing follow-up of 
500 abatacept-treated patients.
In a small series, neutralizing antibodies to abatacept 
were  found  in  six  of  nine  (67%)  of  rheumatoid 
Table 6 Summary of safety data from abatacept studies
Open-label, lead-in  
and controlled  
withdrawal phases
Open-label,  
long-term  
extension
Number of patients 190 153
Study length (months) 10 35 (47.8 maximum)
Patient-year exposure NA NA
Adverse events (total) 170 NA
Serious adverse events  
(total)
6 23
Adverse events leading  
to drug discontinuation
1 3
infusion reactions  9 15 (5 patients)
Anaphylaxis-like reactions 0 2
infections (total) 95 NA
Serious infections 1 6
Mycobacterium infections 0 0
Other opportunistic 
infections
0 1
Autoimmune phenomena  
(total)
0 0
Uveitis 0 1
Demyelinating events 0 1
“Lupus-like” syndrome 0 0
Autoantibodies 14 4
Antibodies to medication NA 17
Malignancies (total) 1* 0
Deaths 0 0
Note: *Malignancy may have been prior to treatment and patient was misdiagnosed 
with juvenile idiopathic arthritis.
Adapted from Hashkes et al.15
Abbreviation: NA, not available. Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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  factor-positive patients.31 However, these antibodies were 
not associated with disease flare or adverse events. Antibodies 
were found more often when abatacept concentrations were 
below therapeutic levels.
Indications and practical issues
In 2008, the FDA approved abatacept for use in children older 
than six years with moderate to severe JIA of polyarticular 
course. The drug can be used as monotherapy or in conjunc-
tion with other nonbiologic disease-modifying antirheumatic 
drugs. In 2010, the European Medicines Agency approved 
abatacept in combination with methotrexate only in children 
who have failed disease-modifying antirheumatic drugs and 
at least one TNF-α blockade agent.
Abatacept is administered as an intravenous infusion 
over a period of 30 minutes. It is given every two weeks 
during the first month and then every four weeks at a dose of 
10 mg/kg (maximum 1000 mg). Premedication for infusion 
reactions is not necessary. Tuberculosis and viral hepatitis 
status should be checked before treatment. Live vaccines 
should be avoided while taking the medication and until three 
months after discontinuation of the drug. Abatacept contains 
maltose that can cause a false elevation of blood glucose for 
up to one day after the infusion.
In a recent study from Canada, the costs of biologics 
versus conventional therapy in patients having JIA with 
a polyarticular course who failed or were intolerant to 
disease-modifying antirheumatic drugs, were calculated.32 
The study compared the costs (direct and indirect, eg, cost 
of adverse events) involved in giving etanercept, infliximab, 
adalimumab, and abatacept for one year in order to attain 
an additional patient who achieved an ACR Pediatric 30 
response status. Of the four drugs, abatacept was the least 
expensive, with a cost of US $16,205 per year to achieve 
one patient with an ACR Pediatric 30 response.
Abatacept versus TNF-α blockers
The lack of head-to-head studies makes it difficult to compare 
these medications accurately. It appears that the efficacy is 
comparable, with a similar proportion of patients experienc-
ing an ACR Pediatric 30 and higher levels of response.10–12,25 
However, abatacept may take somewhat longer to achieve a 
response than TNF-α blockers. The time to flare appears to 
be longer, and the proportions of patients who flare appears 
to be smaller when abatacept is withdrawn compared with 
TNF-α blockers. In regards to safety issues, the number of 
patient-years of use for abatacept is still insufficient to com-
pare it with TNF-α blockers, particularly for malignancies. 
However, there do not appear to be significant differences 
regarding serious infectious adverse events, with the excep-
tion of mycobacterium infections, which are probably less 
common in abatacept-treated patients.15 Infusion reactions 
occur less frequently with abatacept than with infliximab.
Future indications  
and directions in JIA
Several case series have reported on the successful use of 
abatacept for JIA-related uveitis among TNF-α blockade 
failures.33,34 No studies have been published on the use 
of abatacept for systemic (with active systemic features), 
juvenile psoriatic, and enthesitis-related arthritis. Studies 
directly comparing abatacept with TNF-α blocking agents, 
abatacept with or without methotrexate, and abatacept use 
in early polyarthritis have not been performed. The effect 
of abatacept on the progression of radiologic damage as 
seen in adults should be investigated in the pediatric setting 
using newly validated pediatric measures.35,36 Recent reports 
in adults showing that subcutaneous abatacept may be as 
  effective as the intravenous route, and may offer a new, easier 
method of administration in children.37
Potential of genomic medicine
In the future, it will be possible to personalize and adjust 
correct treatment for the individual patient. The protein 
tyrosine phosphatase nonreceptor type (PTPN) 22 gene, 
located on chromosome 1p13.3-13.1, encodes for a tyrosine 
phosphatase that downregulates the activation of T lympho-
cytes mediated by CD28 costimulation.38 A single nucleotide 
polymorphism in the PTPN22 gene (C1858T) causes a 
decrease in its activity. This polymorphism is more commonly 
found in patients with rheumatoid arthritis, rheumatoid fac-
tor-negative polyarthritis JIA, oligoarthritis, systemic lupus 
erythematosus, and diabetes mellitus.39,40 Due to the effect of 
this polymorphism in enhancing T cell costimulation, there 
is an as yet untested hypothesis that abatacept will be more 
effective in patients with this polymorphism.41 Genomic 
medicine may also enable us to predict which patients are 
more likely to fail TNF-α blockade therapy and benefit from 
earlier use of abatacept.
Conclusion
Abatacept is an immune-modulating drug, targeting 
T cell activation by interfering with one of the costimulatory 
mechanisms that are essential for cell activation. The drug is 
effective in patients with moderate to severe JIA of   polyarticular 
course, either as monotherapy or in combination with other Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
69
Abatacept for polyarticular JiA
nonbiologic disease-modifying antirheumatic drugs. Even 
after more than three years of use, the drug remains safe, with 
rare serious adverse events. However, long-term postmarket-
ing surveillance is necessary. For some patients, the time to 
response from the start of treatment may take as long as six 
months. In most patients, abatacept continues to be effective 
for at least three years. There is also a significant positive 
effect of abatacept on various aspects of health-related qual-
ity of life. Furthermore, abatacept may be more cost-effective 
than TNF-α blocking agents in treating patients with JIA of 
polyarticular course. Therefore, it is possible that the European 
Medicines Agency indication may be modified to allow for 
earlier use of abatacept, even prior to TNF-α blockade failure. 
Future studies may include new indications for abatacept in 
other categories of JIA and JIA-related uveitis, as well as the 
optimal timing of abatacept use in relation to disease onset. In 
the future, we might be able to tailor the use of abatacept for 
patients whose genetics will predict a better response.
Disclosure
The authors report no conflicts of interests in this work.
References
  1.  Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 
369(9563):767–778.
  2.  Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: Outcome 
and treatment for the 1990s. Rheum Dis Clin North Am. 1991;17(4): 
891–905.
  3.  Packham JC, Hall MA, Pimm TJ. Long-term follow-up of 246 adults 
with JIA: Predictive factors for mood and pain. Rheumatology (Oxford). 
2002;41(12):1444–1449.
  4.  Minden K. Adult outcomes of patients with JIA. Horm Res. 2009; 
72 Suppl 1:20–25.
  5.  Ruperto N, Levinson JE, Ravelli A, et al. Long-term health outcomes 
and quality of life in American and Italian inception cohorts of patients 
with juvenile rheumatoid arthritis. I. Outcome status. J Rheumatol. 
1997;24(5):945–951.
  6.  Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns 
of clinical remission in select categories of JIA. Arthritis Rheum. 2005; 
52(11):3554–3562.
  7.  Hashkes PJ, Laxer RM. Medical treatment of JIA. JAMA. 2005; 
294(13):1671–1684.
  8.  Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant 
juvenile rheumatoid arthritis. Results of the USA-USSR. double-blind, 
placebo-controlled trial. The Pediatric Rheumatology Collaborative 
Study Group and The Cooperative Children’s Study Group. N Engl 
J Med. 1992;326(16):1043–1049.
  9.  Ruperto N, Murray KJ, Gerloni V , et al. A randomized trial of parenteral 
methotrexate comparing an intermediate dose with a higher dose in 
children with JIA who failed to respond to standard doses of methotrex-
ate. Arthritis Rheum. 2004;50(7):2191–2201.
  10.  Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with 
polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology 
Collaborative Study Group. N Engl J Med. 2000;342(11):763–769.
  11.  Ruperto N, Lovell DJ, Cuttica R, et al. A randomized,   placebo-controlled 
trial of infliximab plus methotrexate for the treatment of polyarticular-
course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9): 
3096–3106.
  12.  Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without 
methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008; 
359(8):810–820.
  13.  Ringold S, Seidel KD, Koepsell TD, Wallace CA. Inactive disease in 
polyarticular JIA: Current patterns and associations. Rheumatology 
(Oxford). 2009;48(8):972–977.
  14.  Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to 
eight years of continuous etanercept therapy in patients with juvenile 
rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496–1504.
  15.  Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic therapies 
for JIA. Nat Rev Rheumatol. 2010;6(10):561–571.
  16.  Macaubas C, Nguyen K, Milojevic D, Park JL, Mellins ED. Oligoar-
ticular and polyarticular JIA: Epidemiology and pathogenesis. Nat Rev 
Rheumatol. 2009;5(11):616–626.
  17.  Nistala K, Wedderburn LR. Th17 and regulatory T cells:   Rebalancing 
pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology 
(Oxford). 2009;48(6):602–606.
  18.  Prakken BJ, Albani S. Using biology of disease to understand and guide 
therapy of JIA. Best Pract Res Clin Rheumatol. 2009;23(5): 599–608.
  19.  Hervey PS, Keam SJ. Abatacept. BioDrugs. 2006;20(1):53–61.
  20.  Goeb V, Buch MH, Vital EM, Emery P. Costimulation blockade 
in rheumatic diseases: Where we are? Curr Opin Rheumatol. 2009; 
21(3):244–250.
  21.  Graca L. CTLA4Ig and the therapeutic potential of T cell co-stimulation 
blockade. Acta Reumatol Port. 2008;33(3):267–276. [Portuguese].
  22.  Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of 
the selective co-stimulation modulator abatacept following 2 years 
of treatment in patients with rheumatoid arthritis and an inadequate 
response to anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008; 
67(4):547–554.
  23.  Orencia® [Package insert]. Princeton, NJ: Bristol-Myers Squibb 
  Company; Aug 2009.
  24.  Bruce SP, Boyce EG. Update on abatacept: A selective costimula-
tion modulator for rheumatoid arthritis. Ann Pharmacother. 2007; 
41(7):1153–1162.
  25.  Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with 
JIA: A randomised, double-blind, placebo-controlled withdrawal trial. 
Lancet. 2008;372(9636):383–391.
  26.  Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. 
Preliminary definition of improvement in juvenile arthritis. Arthritis 
Rheum. 1997;40(7):1202–1209.
  27.  Ruperto N, Lovell DJ, Quartier P, et al; Paediatric Rheumatology 
International Trials Organization and the Pediatric Rheumatology 
Collaborative Study Group. Long-term safety and efficacy of abatacept 
in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010; 
62(6):1792–1802.
  28.  Ruperto N, Lovell DJ, Li T, et al. Abatacept improves health-related 
quality of life, pain, sleep quality and daily participation in subjects 
with JIA. Arthritis Care Res (Hoboken). 2010;62(11):1542–1551.
  29.  Ruperto N, Ravelli A, Pistorio A, et al. Cross-cultural adaptation 
and psychometric evaluation of the Childhood Health Assessment 
Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 
32 countries. Review of the general methodology. Clin Exp Rheumatol. 
2001;19(4 Suppl 23):S1–S9.
  30.  Durmoqicz EL. Pediatric focused safety review. FDA [online]. 
  Available from: http://www.fda.gov/downloads/AdvisoryCommittees/ 
CommitteesMeetingMaterials/PediatricAdvisoryCommittee/
ucm193143.pdf. Accessed 2010 Dec 21.
  31.  Kuemmerle-Deschner JB, Benseler S. Abatacept in difficult-to-treat 
JIA. Biologics. 2008;2(4):865–874.
  32.  Ungar WJ, Costa V, Hancock-Howard R, Feldman BM, Laxer RM. 
Cost-effectiveness of biologics in polyarticular-course JIA patients 
unresponsive to disease modifying anti-rheumatic drugs. Arthritis Care 
Res (Hoboken).2011;63(1):111–119.
  33.  Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor 
necrosis factor alpha refractory JIA-related uveitis. Arthritis Care Res 
(Hoboken). 2010;62(6):821–825.Drug Design, Development and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal
Drug Design, Development and Therapy is an international, peer-
reviewed open-access journal that spans the spectrum of drug design 
and development through to clinical applications. Clinical outcomes, 
patient safety, and programs for the development and effective, safe, 
and sustained use of medicines are a feature of the journal, which 
has also been accepted for indexing on PubMed Central. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
70
Goldzweig and Hashkes
  34.  Kenawy N, Cleary G, Mewar D, Beare N, Chandna A, Pearce I. Abatacept: 
A potential therapy in refractory cases of JIA-associated uveitis. Graefes 
Arch Clin Exp Ophthalmol. Oct 5 2010. [Epub ahead of print].
  35.  Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation 
modulation in patients with undifferentiated inflammatory arthritis 
or very early rheumatoid arthritis: A clinical and imaging study of 
  abatacept (the ADJUST trial). Ann Rheum Dis. 2010;69(3):510–516.
  36.  Ravelli A, Ioseliani M, Norambuena X, et al. Adapted versions of the Sharp/
van der Heijde score are reliable and valid for assessment of   radiographic 
progression in JIA. Arthritis Rheum. 2007;56(9): 3087–3095.
  37.  Keystone EC, Kremer JM, Russell AS, et al. Switching patients with 
rheumatoid arthritis (RA) from intravenous (IV) to subcutaneous (SC) 
abatacept is well tolerated and sustains previously established efficacy 
[Abstract]. Arthritis Rheum. 2010;62(10 Suppl):S176.
  38.  Hinks A, Worthington J, Thomson W. The association of PTPN22 
with rheumatoid arthritis and JIA. Rheumatology (Oxford). 2006; 
45(4):365–368.
  39.  Lee YH, Rho YH, Choi SJ, et al. The PTPN22 C1858T functional 
polymorphism and autoimmune diseases – a meta-analysis. 
Rheumatology (Oxford). 2007;46(1):49–56.
  40.  Thompson SD, Sudman M, Ramos PS, et al. The susceptibility loci JIA 
shares with other autoimmune diseases extend to PTPN2, COG6, and 
ANGPT1. Arthritis Rheum. 2010;62(11):3265–3276.
  41.  Gregersen PK, Lee HS, Batliwalla F, Begovich AB. PTPN22: Setting 
thresholds for autoimmunity. Semin Immunol. 2006;18(4):214–223.